Pfizer Canada has introduced Toviaz (fesoterodine fumarate extended release tablets) that is indicated for the treatment of patients with overactive bladder (OAB) with symptoms of urinary frequency, urgency, or urge incontinence, or any combination of these symptoms, in the Canadian market.
Overactive bladder is a condition that affects one in five Canadian women over the age of 35 and one in seven Canadian men over the age of 35, yet remains under-treated.
Toviaz is the newest addition to Pfizer’s OAB portfolio, and is available available in two doses, 4 mg and 8 mg to be taken once daily.
Pfizer Canada vice-president and medical director Bernard Prigent said given Pfizer Canada’s long heritage in the overactive bladder market with Detrol and Detrol LA, the company understands that experiences and challenges with overactive bladder differ from patient to patient.
"The approval of Toviaz gives Canadian physicians a new option to help address these challenges for patients," Prigent said.
Pfizer Canada received the approval of Toviaz by Health Canada based on two Phase 3 randomized, double-blind, placebo-controlled, 12-week studies.
The safety of Toviaz was primarily evaluated in Phase 2 and 3 controlled trials in a total of 2,859 patients with overactive bladder of which 2,288 were treated with fesoterodine.